- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
SeQuent Scientific shines in Q1 FY26: Revenue +13% to ₹441.4 Cr, EBITDA +24.7% to ₹60.2 Cr, PAT +93.7%. API business hit ₹105.4 Cr. Viyash also strong: Revenue +4% to ₹353 Cr, EBITDA +19% to ₹68 Cr, with robust regulatory clearances. Combined, revenue +8.7%, EBITDA +21% to ₹129 Cr. Merger on track for shareholder meeting on Aug 30. Management is bullish on growth, margin expansion (targeting 50% for SeQuent, 20% combined by FY27), and realizing major synergies from R&D, manufacturing, and cost efficiencies post-merger. A confident outlook on future value creation.